Aclarion Authorizes $2.5 Million Stock Buyback, Signaling Confidence in Nociscan Growth
Aclarion's board-approved share repurchase program highlights the company's disciplined capital management and belief that its stock is undervalued despite the ongoing clinical adoption of its Nociscan platform for chronic back pain diagnosis.
Aclarion, Inc. announced that its Board of Directors has authorized a share repurchase program of up to $2.5 million of the company's outstanding common stock. The commercial-stage healthcare technology company, which leverages biomarkers and proprietary augmented intelligence algorithms through its Nociscan platform, expects to execute the repurchases over the next twelve months. The program is funded by existing cash and cash equivalents, with the company reporting approximately $19.0 million in cash as of March 31, 2026.
Chief Executive Officer Brent Ness stated the authorization underscores a commitment to disciplined capital allocation and reflects management's belief that Aclarion's current valuation does not fully reflect the strength of its platform and long-term growth opportunity. "We believe our shares represent a compelling value at current levels, and we view this program as a flexible and opportunistic tool to enhance shareholder value while continuing to invest in the clinical adoption and expansion of Nociscan," Ness said. The timing and volume of repurchases will depend on market conditions, share price, liquidity, and strategic priorities, and the program may be suspended or discontinued at any time.
Chief Financial Officer Greg Gould emphasized the balance between growth investment and prudent capital management. "Given our current capital position and expected operating needs, we believe a share repurchase program is an efficient and disciplined way to deploy capital while maintaining the financial flexibility necessary to execute on our strategic priorities," Gould explained. Management believes the $19.0 million cash position provides sufficient runway to support operations through key upcoming milestones, including the initial milestone of the CLARITY randomized trial for Nociscan.
The Nociscan platform is designed to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine, providing insights to optimize treatment strategies for chronic low back pain. Repurchases may be made through various methods, including open market purchases and transactions under Rule 10b5-1 plans. For more information on the company, please visit www.aclarion.com. The latest news and updates relating to Aclarion are also available in the company’s newsroom at https://tinyurl.com/aconnewsroom.